HEALTH TECHNOLOGY APPRAISAL:
CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY (2ND ACD)

To: NICE       FROM: NHS Quality Improvement Scotland

Reviewer 1

i) Whether you consider that all the relevant evidence has been taken into account.

YES

ii) Whether you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence and that the preliminary views on the resource impact and implications for the NHS are appropriate.

YES

iii) Whether you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS.

YES

Reviewer 2

i) Whether you consider that all the relevant evidence has been taken into account.

This document does take into consideration representation from Health professionals relating to the concerns about a small group of ESRD patients
with refractory hyperparathyroidism with relative or absolute contra-
indications to surgical parathyroidectomy. I would agree that all relevant
evidence has been taken into account but accept the reservations of the
Committee that there is a paucity of RCT evidence to support use of cinacalcet
in these specific 'problem' groups.

ii) Whether you consider that the summaries of clinical and cost effectiveness are
reasonable interpretations of the evidence and that the preliminary views on
the resource impact and implications for the NHS are appropriate.  Yes

iii) Whether you consider that the provisional recommendations of the Appraisal
Committee are sound and constitute a suitable basis for the preparation of
guidance to the NHS.

They are a significant improvement on the earlier recommendations and
address the needs of a group of patients where treatment options are currently
limited or ineffective. The 'check' of a 30% improvement at 3 months will
prevent inappropriate and costly prolonged use of the drug.

Reviewer 3.

i) Whether you consider that all the relevant evidence has been taken into
account.

Yes

ii) Whether you consider that the summaries of clinical and cost effectiveness are
reasonable interpretations of the evidence and that the preliminary views on
the resource impact and implications for the NHS are appropriate.

Yes

iii) Whether you consider that the provisional recommendations of the Appraisal
Committee are sound and constitute a suitable basis for the preparation of
guidance to the NHS.

Yes

7 September 2006